BLASUBCUTANEOUSPOWDERPriority Review
Approved
Nov 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
REBLOZYL (luspatercept) by Bristol Myers Squibb. Approved for erythroid maturation agent [epc]. First approved in 2019.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REBLOZYL (luspatercept) is an erythroid maturation agent approved in 2019 for treating anemia in patients with myelodysplastic syndromes and beta-thalassemia. It works by promoting late-stage erythroid maturation, reducing ineffective erythropoiesis and transfusion dependency. Administered subcutaneously as a powder formulation.
$26MPart D
PeakThe product is at peak commercial maturity with growing adoption in specialized hematology markets, indicating stable medium-sized teams focused on market penetration and patient access.
Mechanism of Action
Pharmacologic Class:
Erythroid Maturation Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms
Started Aug 2026
190 enrolled
Myelodysplastic Neoplasms
A Study of Luspatercept in People With Anemia
Started Jul 2026
30 enrolled
AnemiaChronic Kidney Disease
A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East
Started Jun 2026
200 enrolled
β-thalassemia
Luspatercept + Darbepoetin in MDS
Started Dec 2025
60 enrolled
MDS (Myelodysplastic Syndrome)
Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China
Started Apr 2025
88 enrolled
Myelodysplastic Syndromes
Worked on REBLOZYL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.